Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | SAT1 | P21673 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683460 | 0.82 | SAT1 (0.48) | DPP4SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL12518238 | 0.79 | SAT1 (0.42) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL19700576 | 0.79 | SAT1 (0.41) | DPP4SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL17471139 | 0.79 | GNAO1 (0.44) | GNAI3GNAO1GNAI1 | |
| SCHEMBL8048307 | 0.77 | ADH1B (0.42) | DPP4SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL14593629 | 0.77 | HTT (0.30) | — | |
| SCHEMBL8034171 | 0.76 | GNAI3 (0.56) | DPP4SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL1915412 | 0.75 | L3MBTL1 (0.39) | SIGMAR1 | |
| SCHEMBL6182975 | 0.74 | HRH4 (0.34) | DPP4GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL21128452 | 0.74 | BCHE (0.38) | CACNA1IKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | DPP4 4011/4885SAT1 4205/4885GNAI3 935/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | DPP4 4011/4885SAT1 4205/4885GNAI3 935/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | DPP4 3711/4885SAT1 4020/4885GNAI3 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.